InflaRx N.V. (IFRX)
| Market Cap | 119.79M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -38.26M |
| Shares Out | 44.20M |
| EPS (ttm) | -1.27 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 713,696 |
| Open | 2.98 |
| Previous Close | 2.99 |
| Day's Range | 2.26 - 3.05 |
| 52-Week Range | 0.78 - 5.69 |
| Beta | 1.29 |
| Analysts | Buy |
| Price Target | 5.10 (+88.2%) |
| Earnings Date | Aug 8, 2022 |
About IFRX
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemi... [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for IFRX stock is "Buy." The 12-month stock price forecast is 5.1, which is an increase of 88.19% from the latest price.
News
InflaRx N.V. (IFRX) Upgraded to Buy: What Does It Mean for the Stock?
InflaRx N.V. (IFRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
InflaRx Reports Second Quarter 2022 Financial & Operating Results
JENA, Germany, Aug. 05, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, ann...
Why Is InflaRx (IFRX) Stock Up 40% Today?
InflaRx (NASDAQ: IFRX ), a maker of anti-inflammatory therapeutics, is up 40% today after announcing it's pursuing emergency-use authorization from the U.S. Food and Drug Administration for its Covid-19...
InflaRx Announces Plans to Apply for Emergency Use Authorization from the US FDA for Vilobelimab for Treatment of Cri...
JENA, Germany, July 26, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, tod...
InflaRx Receives FDA Fast Track Designation for Treatment of Ulcerative Pyoderma Gangrenosum
JENA, Germany, July 06, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, tod...
InflaRx Provides Development Update For Vilobelimab In Skin Disorder, COVID-19
InflaRx N.V. (NASDAQ: IFRX) provided a development update for its monoclonal anti-C5a antibody, vilobelimab, in pyoderma gangrenosum (PG) and severe COVID-19.
InflaRx Provides Development Update for Vilobelimab in Pyoderma Gangrenosum and Severe COVID-19
JENA, Germany, June 29, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, pro...
InflaRx to Present at the H.C. Wainwright Global Investment Conference
JENA, Germany, May 17, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, toda...
InflaRx Reports First Quarter 2022 Financial and Operating Results and Provides Strategic Update
JENA, Germany, May 12, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, anno...
InflaRx Shares Plunge After Disappointing Results On Vilobelimab In Critically Ill COVID-19 Patients
InflaRx N.V. (NASDAQ: IFRX) announced topline data from Phase 3 part of Phase 2/3 PANAMO study of vilobelimab in critically ill COVID-19 patients.
InflaRx Announces Encouraging Phase III Topline Results from PANAMO Trial of Vilobelimab in Severe COVID-19 Patients
JENA, Germany, March 31, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, an...
InflaRx N.V. (IFRX) Reports Q4 Loss, Misses Revenue Estimates
InflaRx N.V. (IFRX) delivered earnings and revenue surprises of 10.81% and 100%, respectively, for the quarter ended December 2021.
InflaRx Reports Full Year 2021 Financial and Operating Results
JENA, Germany, March 24, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, an...
FDA Issues Corrected Advice To InflaRx's Vilobelimab Study In Skin Disease
InflaRx N.V. (NASDAQ: IFRX) has received a corrected advice letter from the FDA regarding its Phase 3 vilobelimab program for hidradenitis suppurativa (HS).
InflaRx Receives Corrected Advice Letter from FDA Related to Phase III Program for Vilobelimab in Hidradenitis Suppur...
JENA, Germany, March 17, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, to...
InflaRx Announces Vilobelimab Trial in Pyoderma Gangrenosum Selected for Late-Breaker Oral Presentation at 2022 AAD A...
JENA, Germany, March 08, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, an...
InflaRx Provides Update on Development Plans for Vilobelimab in Hidradenitis Suppurativa
JENA, Germany, Feb. 28, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, tod...
See Why Did InflaRx Pause Late-Stage Vilobelimab Trial In Chronic Skin Condition
InflaRx N.V. (NASDAQ: IFRX) has received an advice letter from the FDA about the vilobelimab Phase 3 program for hidradenitis suppurativa (HS), a condition that causes small, painful lumps to form under...
InflaRx Reports Progress in Ongoing Phase II Clinical Trial with Vilobelimab in Cutaneous Squamous Cell Carcinoma
JENA, Germany, Feb. 16, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, tod...
InflaRx to Present at Annual SVB Leerink Global Health Conference
JENA, Germany, Feb. 08, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, wil...
InflaRx Announces New Pipeline Program – Oral C5aR Inhibitor
JENA, Germany, Jan. 10, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, tod...
InflaRx Announces Presentation at J.P. Morgan Healthcare Conference and Other Investor Events
JENA, Germany, Jan. 05, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, tod...
InflaRx Initiates Phase III Clinical Program with Vilobelimab in Hidradenitis Suppurativa
JENA, Germany, Jan. 05, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, tod...
InflaRx's Vilobelimab Shows Encouraging Action Against Rare Autoimmune Disorder
InflaRx N.V. (NASDAQ: IFRX) has announced data from the European Phase II IXCHANGE study of vilobelimab in patients with ANCA-associated vasculitis (AAV).
InflaRx Announces Positive Data from Phase II IXCHANGE Study with Vilobelimab in ANCA-associated Vasculitis (AAV)
JENA, Germany, Nov. 15, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, tod...